David Soper

David Soper has a diverse work experience in scientific roles. David began their career at Nodality Inc. in 2008 as a Scientist, where they focused on examining cell signaling networks using quantitative phospho-flow cytometry for cancer treatment decision-making. David then worked as a Senior Scientist at a medical device startup from 2011 to 2012. In 2012, they joined Quest Diagnostics as a Senior Scientist in Flow Cytometry, where they designed and developed assays for clinical trials. Since 2013, David has been working at BioLegend, starting as a Scientist III and progressing to Head and currently Director of Emerging Technology.

David Soper completed their education in a chronological order. David started their academic journey in 1998 at the University of California, Berkeley, where they pursued a Bachelor of Arts degree in Molecular and Cell Biology with an emphasis in Immunology. David completed this degree in 2002. Following their undergraduate studies, David enrolled at the University of Washington - School of Medicine in 2002 to pursue a PhD in Immunology. David successfully completed their doctoral program in 2007.